Charles River Laboratories has reported its second-quarter earnings, with the CRO seeing revenue decline from $1.06 billion in the second quarter of last year to $1.03 billion. Demand for the company’s services is likely to continue its downward trajectory through the rest of the year, according to an Aug. 7 release.

Fierce Biotech Associate Editor Gabrielle Masson presented the 2024 class of Fierce 15 winners on the floor of the New York Stock Exchange on Wednesday.

Precigen is throwing everything behind a push to bring a noncancerous tumor gene therapy to market, driving it to lay off 20% of its employees and pause a raft of other programs to stretch its limited funds.

Three weeks after Roche’s Genentech unit walked away from an SHP2 inhibitor pact, Relay Therapeutics has confirmed that it won’t be pushing ahead with the asset solo.

Full-service contract research organization Rho has named neurologist Andrew Feigin, M.D., its new chief medical officer. Feigin is an expert in movement disorders such as Parkinson’s disease.

Asset manager TPG, which has supported biotechs such as Sionna Therapeutics and Santa Ana Bio, has topped up its Life Science Innovations fund, bringing total capital raised for the effort to $580 million.

Big Pharmas remain stuck to the idea of molecular glue degraders. The latest company to see an opportunity is Japan’s Eisai, which has signed a $1.5 billion biobucks pact with SEED Therapeutics for undisclosed neurodegeneration and oncology targets.

Merck & Co. has quickly recouped some of the costs of its Harpoon Therapeutics buyout, pulling in $170 million upfront by incorporating the lead candidate into a co-development deal with Daiichi Sankyo.

Biogen and Novartis may have walked away from partnerships with Sangamo Therapeutics last year, but that hasn’t stopped Roche from seeking out a pact with the biotech to work on intravenous genomic medicines for neurodegenerative diseases.

Special pharmaceutical company Mallinckrodt is selling its photopheresis business, Therakos, to CVC Capital Partners for $925 million.